Novel therapeutic approaches to post-infarction remodelling.

Adverse cardiac remodelling is a major cause of morbidity and mortality following acute myocardial infarction (MI). Mechanical and neurohumoral factors involved in structural and molecular post-infarction remodelling were important targets in research and treatment for years. More recently, therapeutic strategies that address myocardial regeneration and pathophysiological mechanisms of infarct wound healing appear to be useful novel tools to prevent progressive ventricular dilation, functional deterioration, life-threatening arrhythmia, and heart failure. This review provides an overview of future and emerging therapies for cardiac wound healing and remodelling after MI.

[1]  G. Fan,et al.  Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. , 2012, Cardiovascular research.

[2]  B. Schroen,et al.  Small but smart--microRNAs in the centre of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and ageing. , 2012, Cardiovascular research.

[3]  D. Kass,et al.  Subcellular Structures and Function of Myocytes Impaired During Heart Failure Are Restored by Cardiac Resynchronization Therapy , 2012, Circulation research.

[4]  Marcus F Stoddard,et al.  Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial , 2011, The Lancet.

[5]  J. Rasko,et al.  Promises and Challenges of Stem Cell Research for Regenerative Medicine , 2011, Annals of Internal Medicine.

[6]  M. V. van Zandvoort,et al.  Blocking of Frizzled Signaling With a Homologous Peptide Fragment of Wnt3a/Wnt5a Reduces Infarct Expansion and Prevents the Development of Heart Failure After Myocardial Infarction , 2011, Circulation.

[7]  N. Frangogiannis,et al.  Transforming growth factor (TGF)-β signaling in cardiac remodeling. , 2011, Journal of molecular and cellular cardiology.

[8]  G. Alunni,et al.  Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony. , 2011, JACC. Cardiovascular imaging.

[9]  P. Anversa,et al.  Role of Cardiac Stem Cells in Cardiac Pathophysiology: A Paradigm Shift in Human Myocardial Biology , 2011, Circulation research.

[10]  P. Nguyen,et al.  Novel MicroRNA Prosurvival Cocktail for Improving Engraftment and Function of Cardiac Progenitor Cell Transplantation , 2011, Circulation.

[11]  B. Strauer,et al.  10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. , 2011, Journal of the American College of Cardiology.

[12]  B. Byrne,et al.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  P. Williams,et al.  Plasmid-mediated gene therapy for cardiovascular disease. , 2011, Cardiovascular research.

[14]  Daniel G. Anderson,et al.  Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.

[15]  T. Tuschl,et al.  MicroRNA-24 Regulates Vascularity After Myocardial Infarction , 2011, Circulation.

[16]  J Hartikainen,et al.  Progress and prospects: hurdles to cardiovascular gene therapy clinical trials , 2011, Gene Therapy.

[17]  J. Bauersachs,et al.  Biogenesis and Regulation of Cardiovascular MicroRNAs , 2011, Circulation Research.

[18]  Yan Lu,et al.  Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization , 2011, Basic Research in Cardiology.

[19]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[20]  P. Doevendans,et al.  Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. , 2011, European heart journal.

[21]  B. Klein,et al.  Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. , 2011, European heart journal.

[22]  E. Marbán,et al.  Cardiac cell therapy: where we've been, where we are, and where we should be headed. , 2011, British medical bulletin.

[23]  R. Hinkel,et al.  Gene therapy for ischemic heart disease , 2011, Expert opinion on biological therapy.

[24]  R. Hajjar,et al.  Cardiac gene therapy with SERCA2a: from bench to bedside. , 2011, Journal of molecular and cellular cardiology.

[25]  U. Landmesser,et al.  Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. , 2011, European heart journal.

[26]  S. Butz,et al.  GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice , 2011, Nature Medicine.

[27]  S. Gundewar,et al.  Gene therapy for ischemic heart disease. , 2011, Journal of molecular and cellular cardiology.

[28]  Richard T. Lee,et al.  Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. , 2011, Cell stem cell.

[29]  F. Prósper,et al.  Adipose-derived Stem Cells for Myocardial Infarction , 2011, Journal of cardiovascular translational research.

[30]  J. Fischer,et al.  Deficiency of Biglycan Causes Cardiac Fibroblasts to Differentiate into a Myofibroblast Phenotype* , 2011, The Journal of Biological Chemistry.

[31]  Yoshiaki Kawase,et al.  Rescuing the failing heart by targeted gene transfer. , 2011, Journal of the American College of Cardiology.

[32]  T. Noda,et al.  Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury , 2011, Circulation.

[33]  F. Spinale,et al.  Myocardial remodeling: cellular and extracellular events and targets. , 2011, Annual review of physiology.

[34]  P. Serruys,et al.  Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[35]  P. Galuppo,et al.  Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction , 2011, Circulation.

[36]  E. Olson,et al.  Pervasive roles of microRNAs in cardiovascular biology , 2011, Nature.

[37]  J. Leor,et al.  Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair , 2011, Proceedings of the National Academy of Sciences.

[38]  J. Bauersachs.  Regulation of Myocardial Fibrosis by MicroRNAs , 2010, Journal of cardiovascular pharmacology.

[39]  B. Walker,et al.  Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI. , 2010, Cardiovascular research.

[40]  S. Solomon,et al.  Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to Outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy , 2010, Circulation.

[41]  G. Schütz,et al.  Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. , 2010, The Journal of clinical investigation.

[42]  Jeroen J. Bax,et al.  Critical appraisal of the use of cardiac resynchronization therapy beyond current guidelines. , 2010, Journal of the American College of Cardiology.

[43]  Xiao-Fan Wang,et al.  Smad3 Signaling Critically Regulates Fibroblast Phenotype and Function in Healing Myocardial Infarction , 2010, Circulation research.

[44]  S. Rensen,et al.  Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. , 2010, Cardiovascular research.

[45]  A. Mathur,et al.  Cardiac stem cell therapy: progress from the bench to bedside , 2010, Heart.

[46]  B. Jugdutt.  Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans. , 2010, Circulation.

[47]  H. Drexler,et al.  Continuous Glycoprotein-130-Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction , 2010, Circulation.

[48]  M. Pittet,et al.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. , 2010, Circulation.

[49]  S. Seth,et al.  The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial a long-term follow-up study. , 2010, Journal of the American College of Cardiology.

[50]  H. Drexler,et al.  Cell therapy for the treatment of coronary heart disease: a critical appraisal , 2010, Nature Reviews Cardiology.

[51]  N. Frangogiannis,et al.  The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. , 2010, Journal of molecular and cellular cardiology.

[52]  M. Taljaard,et al.  Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. , 2010, American heart journal.

[53]  Wei-Jan Chen,et al.  Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor‐β1 in cultured cardiac fibroblasts , 2010, European journal of heart failure.

[54]  Markus G. Manz,et al.  Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.

[55]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[56]  A. Mihailidou,et al.  Glucocorticoids Activate Cardiac Mineralocorticoid Receptors During Experimental Myocardial Infarction , 2009, Hypertension.

[57]  A. Ganser,et al.  Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. , 2009, European heart journal.

[58]  A. Tager,et al.  Induction of the CXC Chemokine Interferon-&ggr;–Inducible Protein 10 Regulates the Reparative Response Following Myocardial Infarction , 2009, Circulation research.

[59]  G. Filippatos,et al.  Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial † , 2009, European journal of heart failure.

[60]  H. Arnesen,et al.  Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study , 2009, Heart.

[61]  Jörn Tongers,et al.  Human studies of angiogenic gene therapy. , 2009, Circulation research.

[62]  C. Garlanda,et al.  Macrophage diversity and polarization in atherosclerosis: a question of balance. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[63]  Chunxiang Zhang,et al.  MicroRNA Expression Signature and the Role of MicroRNA-21 in the Early Phase of Acute Myocardial Infarction* , 2009, The Journal of Biological Chemistry.

[64]  T. Akasaka,et al.  Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[65]  Stefanie Dimmeler,et al.  MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice , 2009, Science.

[66]  M. Tendera,et al.  Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem , 2009, European heart journal.

[67]  G. Nuovo,et al.  MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. , 2009, Cardiovascular research.

[68]  G. Dorn.  Novel pharmacotherapies to abrogate postinfarction ventricular remodeling , 2009, Nature Reviews Cardiology.

[69]  F. Geissmann,et al.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells. , 2009, Annual review of immunology.

[70]  Derek J Van Booven,et al.  Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support , 2009, Circulation.

[71]  S. Kostin,et al.  Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction , 2009, Journal of cellular and molecular medicine.

[72]  J. Hartikainen,et al.  Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer , 2009, Gene Therapy.

[73]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[74]  H. Drexler,et al.  Potential novel pharmacological therapies for myocardial remodelling. , 2008, Cardiovascular research.

[75]  M. Lindsey,et al.  Macrophage roles following myocardial infarction. , 2008, International journal of cardiology.

[76]  H. Huikuri,et al.  Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. , 2008, European heart journal.

[77]  G. Ertl,et al.  Post-infarct remodelling: contribution of wound healing and inflammation , 2008, Cardiovascular research.

[78]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[79]  Thomas Thum,et al.  MicroRNAs: novel regulators in cardiac development and disease. , 2008, Cardiovascular research.

[80]  C. Kubal,et al.  Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone , 2008, Nature Clinical Practice Cardiovascular Medicine.

[81]  N. Frangogiannis.  The immune system and cardiac repair. , 2008, Pharmacological research.

[82]  P. Galuppo,et al.  Immediate Mineralocorticoid Receptor Blockade Improves Myocardial Infarct Healing by Modulation of the Inflammatory Response , 2008, Hypertension.

[83]  R. Lüllmann-Rauch,et al.  Biglycan Is Required for Adaptive Remodeling After Myocardial Infarction , 2008, Circulation.

[84]  O. Alfieri,et al.  The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: First Randomized Placebo-Controlled Study of Myoblast Transplantation , 2008, Circulation.

[85]  P. Ponikowski,et al.  Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial , 2008, The Lancet.

[86]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[87]  P. Libby,et al.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions , 2007, The Journal of experimental medicine.

[88]  Sek Won Kong,et al.  Altered microRNA expression in human heart disease. , 2007, Physiological genomics.

[89]  K. Endresen,et al.  Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: results from the Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI) randomized controlled trial. , 2007, American heart journal.

[90]  S. Ylä-Herttuala,et al.  Current status of cardiovascular gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[91]  M. Al-mallah,et al.  Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[92]  N. Frangogiannis,et al.  The role of TGF-β Signaling in Myocardial Infarction and Cardiac Remodeling , 2007 .

[93]  C. Ware,et al.  The FASEB Journal • Research Communication , 2007 .

[94]  Stefan Störk,et al.  Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure , 2007, Circulation.

[95]  Thomas Thum,et al.  MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure , 2007, Circulation.

[96]  M. Harmsen,et al.  Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. , 2007, The American journal of pathology.

[97]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[98]  Minoru Hongo,et al.  Cardiac Overexpression of Monocyte Chemoattractant Protein-1 in Transgenic Mice Prevents Cardiac Dysfunction and Remodeling After Myocardial Infarction , 2006, Circulation research.

[99]  A. Zeiher,et al.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. , 2006, The New England journal of medicine.

[100]  A. Zeiher,et al.  Transcoronary transplantation of progenitor cells after myocardial infarction. , 2006, The New England journal of medicine.

[101]  J. Leor,et al.  Ex Vivo Activated Human Macrophages Improve Healing, Remodeling, and Function of the Infarcted Heart , 2006, Circulation.

[102]  C. Bearzi,et al.  Stem cell niches in the adult mouse heart. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[103]  G. Alunni,et al.  Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. , 2006, Journal of the American College of Cardiology.

[104]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[105]  S. Dymarkowski,et al.  Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial , 2006, The Lancet.

[106]  H. White,et al.  Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. , 2005, Journal of the American College of Cardiology.

[107]  C. Bearzi,et al.  Human cardiac stem cells , 2005, Proceedings of the National Academy of Sciences.

[108]  P. Galuppo,et al.  Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. , 2005, Cardiovascular research.

[109]  B. Rollins,et al.  CCL2/Monocyte Chemoattractant Protein-1 Regulates Inflammatory Responses Critical to Healing Myocardial Infarcts , 2005, Circulation research.

[110]  Michael D. Schneider,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury , 2004, Circulation research.

[111]  Bernd Hertenstein,et al.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial , 2004, The Lancet.

[112]  P. Galuppo,et al.  Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. , 2003, Journal of the American College of Cardiology.

[113]  D. Torella,et al.  Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration , 2003, Cell.

[114]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[115]  A. Zeiher,et al.  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) , 2002, Clinical research in cardiology : official journal of the German Cardiac Society.

[116]  P. Galuppo,et al.  Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. , 2002, Cardiovascular research.

[117]  P. Galuppo,et al.  Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction , 2001, Circulation.

[118]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[119]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[120]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[121]  Doris A Taylor,et al.  Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation , 1998, Nature Medicine.

[122]  G. Lamas,et al.  Ventricular remodeling after myocardial infarction. , 1993, Advances in experimental medicine and biology.

[123]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[124]  M. Gladka,et al.  Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. , 2012, Journal of molecular and cellular cardiology.

[125]  Ayan R Patel,et al.  Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. , 2011, JACC. Cardiovascular imaging.

[126]  Johan Verjans,et al.  Myocardial remodeling after infarction: the role of myofibroblasts , 2010, Nature Reviews Cardiology.

[127]  E. Diethrich,et al.  One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). , 2009, JACC. Cardiovascular interventions.

[128]  Alberto Mantovani,et al.  Macrophage activation and polarization. , 2008, Frontiers in bioscience : a journal and virtual library.

[129]  C. Long,et al.  The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.

[130]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[131]  V. Fadok,et al.  Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. , 2002, The Journal of clinical investigation.

[132]  C A Beltrami,et al.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans. , 1994, Circulation.